REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) announced today that J.J. Finkelstein, RegeneRx's president and chief executive officer, will present a company update at the Rodman & Renshaw Annual Global Investment Conference in New York at 10:20 a.m. ET on Tuesday, November 11.

REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) announced today that J.J. Finkelstein, RegeneRx's president and chief executive officer, will present a company update at the 7th Annual BIO Investor Forum in San Francisco, CA, on Thursday, October 30, 2008 at 2:00 p.m. ET.

Regenerx Biopharmaceuticals has completed enrollment and dosing of 40 healthy subjects for its Phase Ia clinical trial testing RGN-352, an injectable formulation of Tâ4 for potential use in treating acute myocardial infarction patients.

REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that J.J. Finkelstein, RegeneRx's president and chief executive officer was interviewed on "The Leaders Spot", on local Radio Station WMDV 700 AM. Mr.

REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that J.J. Finkelstein, RegeneRx's president and chief executive officer, will present a company update at the BIO InvestorForum 2007 in San Francisco, CA, on October 10, 2007 at 3:45 p.m. EDT.